to Evaluate the Safety and Efficacy of LY011 Cell Injection Targeting CLDN 18.2 Chimeric Antigen Receptor T Cells in the Treatment of Advanced Gastric Adenocarcinoma
Latest Information Update: 25 Sep 2021
At a glance
- Drugs LY 011 (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Sponsors Shanghai Longyao Biotechnology
- 03 Aug 2021 New trial record